Medtronic’s VP Sees Clear Future For Hugo – And Robotic Surgery As A Product Class
Building a surgical robot is hard – even for a company like Medtronic. Rajit Kamal, Medtronic’s VP and Global Leader of Surgical Robotics, explained how the company got to where it has with its Hugo system, and how Medtronic assesses the ever-increasing value of surgical robots to care systems.
Medtech Insight - July 29, 2026

Caldera, Synlogic Reverse Merge To Develop CLD-423 In Inflammatory Bowel Disease
The new company, under the Caldera name, is developing the TL1AxIL-23p19-targeting bispecific to avoid the immunogenicity that anti-TL1A antibodies often cause.
Scrip - July 29, 2026

Biogen Reverses Revenue Growth Trajectory With Apellis In The Fold
Second quarter revenue increased 3% versus a year ago, and the company reversed its forecast for a mid-single digit revenue decline this year to predict growth.
Scrip - July 29, 2026

Executives On The Move: Ex-Merck Exec Takes The Helm At Tessera Therapeutics
Recent moves in the industry include changes at the top at Verdiva Bio, Monopar Therapeutics and Neurocrine Biosciences; internal moves at Sanofi; and Biogen gets a new GM from AstraZeneca.
Scrip - July 29, 2026

Medtronic’s VP Sees Clear Future For Hugo – And Robotic Surgery As A Product Class
Building a surgical robot is hard – even for a company like Medtronic. Rajit Kamal, Medtronic’s VP and Global Leader of Surgical Robotics, explained how the company got to where it has with its Hugo system, and how Medtronic assesses the ever-increasing value of surgical robots to care systems.
In Vivo - July 29, 2026

How To Market An OTC GLP-1 Companion Product In The UK
Exclusive: HBW Insight speaks to the MHRA and ASA about how consumer health companies can legally and compliantly market products designed to support GLP-1 users.
HBW Insight - July 29, 2026

Teva Targets Forty Biosimilars As Generics Growth Stalls
Teva is scaling biosimilars into a major growth driver, targeting nearly 40 products and expecting to exceed its $800m 2027 sales goal as conventional generics remain under pressure.
Generics Bulletin - July 29, 2026

GSK’s Ris-Rez Notches Osteosarcoma Win Ahead Of Prostate Phase III Push
The latest osteosarcoma data further strengthen Ris-Rez's late-stage evidence base as GSK advances the ADC across multiple global registrational studies.
Scrip - July 29, 2026

Feeding Frenzy Looms For Bridion Generics After First US Launches
After the expiry of a key US patent protecting Merck & Co’s Bridion blockbuster, the floodgates have opened for generics, allowing launches into a $1.6bn market – but with more than a dozen firms holding ANDA approvals, competition is set to be fierce.
Generics Bulletin - July 29, 2026

Brazilian Semaglutide Competition Hots Up With Sandoz-Adalvo Approval
Sandoz has set out plans to launch in Brazil by the end of this year its Adalvo-partnered Owozy version of semaglutide, after local regulator Anvisa granted a marketing authorization.
Generics Bulletin - July 29, 2026

Philips Q2 Profit Masks Flat Underlying Margin As Tariff Refund Does The Heavy Lifting
Philips’ Q2 profit jumped, but almost entirely on a one-off €186m US tariff refund. Stripped out, the company’s underlying margin was roughly flat as inflation and tariffs offset growth — and order intake fell for the first time in six quarters.
Medtech Insight - July 29, 2026

Generics Bulletin’s Top 50 Ranking For 2026
This article compiles all the data from Generics Bulletin’s 2026 ranking of the Top 50 companies across the generics and biosimilars industry, including additional details of how the firms’ financial figures compare.
Generics Bulletin - July 29, 2026

NewCo Model For Chinese Assets Entering 2.0 Phase
A NewCo 2.0 phase is developing, shifting to earlier-stage assets, pre-NewCo structures and diversified capital, one investor says. But scarce later-stage assets, regulatory uncertainties and geopolitical risks are likely challenges.
Scrip - July 29, 2026

What Medtech Makers Need To Know About The EU’s New Packaging Rules
The EU's PPWR starts binding packaging obligations on Aug. 12, and there's no blanket medtech exemption. Contact-sensitive device packaging escapes recyclability and recycled-content grades, but conformity assessment, substance limits, EPR and labeling apply in full.
Medtech Insight - July 29, 2026

The Generics Bulletin Top 50, Part Three: Industry Evolution Opens Door To New Players
In the third part of this year’s Generics Bulletin Top 50, we see how industry consolidation and changes in strategy have left gaps in our global ranking for new entrants to fill.
Generics Bulletin - July 29, 2026

Science Corp. First Commercial Launch Of BCI To Restore Central Vision In Germany, UK
A tiny photovoltaic device placed beneath the retina and paired with smart glasses allows users with advanced macular degeneration to read, play cards and use the subway again. The newly CE-marked device heads toward its first commercial implants in Germany and the UK.
Medtech Insight - July 29, 2026